Date:1/14/2009

tual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.

    For further information, please contact

    Dr. Thomas Ramdahl, President & CEO,
    0ystein Soug, CFO,

    +47-23-00-79-90 / +47-913-91-458 (mob),
    +47-23-00-79-84 / +47-906-56-525 (mob),
    post@algeta.com .

    For international enquiries:
    Dr. Mark Swallow / David Dible,
    / Helena Galilee,
    Citigate Dewe Rogerson;

    +44(0)207-638-9571,
    mark.swallow@citigatedr.co.uk .

'/>"/>

SOURCE Algeta Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
2. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
7. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System